Reuters logo
Enzon Pharma cuts more jobs, to stop drug development
December 20, 2012 / 11:35 PM / 5 years ago

Enzon Pharma cuts more jobs, to stop drug development

(Reuters) - Enzon Pharmaceuticals Inc said it will suspend all clinical development activities, days after the cancer drug developer decided to explore a possible sale.

The company, in which activist investor Carl Icahn has a 13.29 percent stake, spent about $4 million last quarter on pipeline research and development and had cash, cash equivalents and marketable securities of $288.7 million as of September 30.

It will also reduce its workforce from 43 employees to about 23-28, Enzon said. Last September, it laid off about half its workforce.

The biotechnology company has two drugs in mid-stage trials and a number of others in early-stage studies.

Enzon, whose revenue mainly comes from royalty payments, will incur about $1.4 million in charges related to the reduction in force and expects to record charges in the first quarter of 2013.

Shares of Enzon, which has a market capitalization of about $200 million, closed at $4.50 on Thursday on the Nasdaq.

Reporting by Prateek Kumar and Balaji Sridharan in Bangalore; Editing by Sreejiraj Eluvangal

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below